Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCLX-001 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies
NCT04836195Phase 1Completed
- Sponsor
- Pacylex Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zelenirstat in B-cell non-Hodgkin lymphoma and solid tumor (advanced stage) (9 arms), sponsored by Pacylex Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose and Dose-Limiting Toxicities and Adverse Events. Started Sep 2021; status: completed.
02
Drugs
zelenirstat
03
Conditions
B-cell non-Hodgkin lymphomasolid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04836195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836195.